Table I.
Socio-demographic, clinical and biomarker data in rheumatoid arthritis patients as compared with healthy controls
| Parameters | Patients | Control | p-value |
|---|---|---|---|
| Age (years) | 40.05 ±7.99 | 40.83 ±8.47 | 0.675 |
| BMI (kg/m2) | 28.11 ±2.27 | 27.45 ±1.24 | 0.081 |
| Gender (male/female) | 22/38 | 10/20 | 0.756 |
| CDAI | 17.52 ±7.38 | – | – |
| DAS28 | 5.81 ±1.74 | – | – |
| CRP (mg/l) | 8.23 ±1.62 | 5.26 ±0.99 | < 0.001 |
| ESR (mm/h) | 67.87 ±21.08 | 12.35 ±4.23 | < 0.001 |
| ACPA +ve/–ve | 34/16 | 0/30 | < 0.001 |
| RF +ve/–ve | 49/11 | 0/30 | < 0.001 |
| Duration of disease (years) median (interquartile range) | 6.21 (0.75–14.66) | – | – |
| Visfatin (ng/ml) | 43.02 ±11.72 | 36.67 ±9.58 | 0.013 |
| Chemerin (ng/ml) | 239.34 ±49.86 | 174.32 ±34.82 | < 0.001 |
| Chemerin/visfatin | 5.88 ±1.69 | 5.09 ±1.67 | 0.041 |
| TC (mM) | 4.65 ±0.82 | 4.19 ±0.89 | 0.019 |
| TG (mM) | 1.36 ±0.15 | 1.27 ±0.13 | 0.005 |
| VLDLc (mM) | 0.62 ±0.07 | 0.58 ±0.06 | 0.005 |
| HDLc (mM) | 0.95 ±0.16 | 1.15 ±0.12 | < 0.001 |
| LDLc (mM) | 3.08 ±0.85 | 2.27 ±0.96 | 0.003 |
| TC/HDLc | 5.08 ±1.41 | 3.75 ±1.10 | < 0.001 |
| TG/HDLc | 1.48 ±0.33 | 1.12 ±0.19 | < 0.001 |
| LDLc/HDLc | 3.40 ±1.32 | 2.24 ±1.05 | < 0.001 |
ACPA – anti-citrullinated peptide/protein antibodies, BMI – body mass index, CDAI – Clinical Disease Activity Index, CRP – C-reactive protein, DAS28 – Disease Activity Score using 28 joints, ESR – erythrocyte sedimentation rate, HDLc – high-density lipoprotein cholesterol, LDLc – low-density lipoprotein cholesterol, RF – rheumatoid factor, TC – total cholesterol, TG – triglyceride, VLDLc – very-low-density lipoprotein cholesterol.